Posted by Michael Wonder on 24 Feb 2020
ContraFect announces U.S. FDA grants breakthrough therapy designation to exebacase for the treatment of Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia, including right-sided endocarditis
24 February 2020 -- ContraFect today announced that that the U.S. FDA has granted breakthrough therapy designation to exebacase for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to standard-of-care anti-staphylococcal antibiotics in adult patients.
The breakthrough therapy designation was based on final data from a Phase 2 superiority trial of exebacase in patients with Staphylococcus aureus bacteraemia, including endocarditis.
